Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear receptor co-repressor
(
N-CoR
) plays important role in transcriptional control mediated by several tumor suppressor proteins. Recently, we reported a role of misfolded-conformation dependent loss (MCDL) of
N-CoR
in the activation of oncogenic survival pathway in acute promyelocytic leukemia (APL). Since
N-CoR
plays important role in cellular homeostasis in various tissues, therefore, we hypothesized that an APL like MCDL of
N-CoR
might also be involved in other malignancy. Indeed, our initial screening of
N-CoR
status in various leukemia and solid tumor cells revealed an APL like MCDL of
N-CoR
in primary and
secondary tumor
cells derived from non-small cell lung cancer (NSCLC). The NSCLC cell specific
N-CoR
loss could be blocked by Kaletra, a clinical grade protease inhibitor and by genistein, an inhibitor of
N-CoR
misfolding previously characterized by us. The misfolded
N-CoR
presented in NSCLC cells was linked to the amplification of ER stress and was subjected to degradation by NSCLC cell specific aberrant protease activity. In NSCLC cells, misfolded
N-CoR
was found to be associated with Hsc70, a molecular chaperone involved in chaperone mediated autophagy (CMA). Genetic and chemical inhibition of Lamp2A, a rate limiting factor of CMA, significantly blocked the loss of
N-CoR
in NSCLC cells, suggesting a crucial role of CMA in
N-CoR
degradation. These findings identify an important role of CMA-induced degradation of misfolded
N-CoR
in the neutralization of ER stress and suggest a possible role of misfolded
N-CoR
protein in the activation of oncogenic survival pathway in NSCLC cells.
...
PMID:Role of chaperone mediated autophagy (CMA) in the degradation of misfolded N-CoR protein in non-small cell lung cancer (NSCLC) cells. 2196 75